What Is Ziconotide Used For? Approved Uses, Per the Label

The short answer

Ziconotide is a prescription medicine in the United States. It is supplied as a sterile solution for intrathecal infusion, meaning delivery into the cerebrospinal fluid through an implanted or external infusion system, and it is marketed under the brand name Prialt. The current United States prescribing information for Prialt (ziconotide intrathecal infusion) carries a single indication: the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Ziconotide is also authorised in the European Union under the same brand name for severe chronic pain in patients who require intrathecal analgesia.

No other indication appears in that labeling. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question of whether a medicine is appropriate for a particular person. Nothing here describes dosing, titration or administration.

The label at a glance

Reading the indication wording

The indication is narrow in three ways that the wording itself makes explicit.

• Severity and chronicity. The indication refers to severe chronic pain, not acute or short lived pain.
• Route selection. It applies to patients for whom intrathecal therapy is already warranted, which places the decision inside a specialist pathway involving an implanted or external delivery system.
• Position in sequence. It applies to patients described as intolerant of or refractory to other treatment, with systemic analgesics, adjunctive therapies and intrathecal morphine given as examples in the labeling.

The label does not restrict the indication to a single disease. Published reviews of intrathecal ziconotide have discussed its use across cancer related pain, pain in advanced illness and chronic nonmalignant pain, with one 2005 palliative care review examining how the agent fitted into end of life pain management services (PMID 16225359). Whether any individual situation matches the labeled indication is a judgement for a prescribing clinician who can examine the patient and the full prescribing information.

How ziconotide works, as described in published reviews

Ziconotide is the synthetic equivalent of omega conotoxin MVIIA, a peptide from the venom of the marine cone snail Conus magus; a review of conotoxins with therapeutic possibilities described this peptide class as selective blockers of neuronal voltage gated calcium channels (PMID 22822370). A 2006 review of ziconotide as a new nonopioid intrathecal analgesic for chronic pain described the agent as acting at N type voltage gated calcium channels in the spinal cord rather than at opioid receptors (PMID 17078783). A review of drug development from marine natural products listed ziconotide among the small set of approved medicines derived from marine organisms and discussed the peptide chemistry that made the molecule developable (PMID 19096380).

That mechanism is the reason the labeling specifies intrathecal delivery. A 2019 laboratory report on a TAT modified version of omega conotoxin MVIIA noted that the native peptide does not readily cross the blood brain barrier and tested a chemical modification intended to improve central access in preclinical models (PMID 31083641). Work of that kind is preclinical and sits outside the approved product.

Evidence behind the approved indication

Reviews published around the time of development and approval describe the clinical program that supported intrathecal ziconotide.

Pre approval evaluation

A 2000 evaluation of intrathecal ziconotide for the treatment of chronic pain, published while the agent was still investigational, summarised the analgesic rationale and the early clinical experience with intrathecal delivery in patients with chronic pain (PMID 11060815). That review predates the approval and therefore describes the agent as a candidate rather than a marketed product.

Randomized controlled evidence as described after approval

A 2006 review of ziconotide as a nonopioid intrathecal analgesic described the randomized, placebo controlled intrathecal studies in adults with severe chronic pain that supported approval, including patients with malignant and nonmalignant pain, and reported that pain relief was achieved in populations whose pain had not responded adequately to other treatment (PMID 17078783). A 2005 palliative care review likewise summarised the controlled trial evidence in patients with cancer and AIDS related pain and discussed how the trial findings translated to hospice and palliative settings (PMID 16225359).

Supporting preclinical analgesia literature

A 2006 report on recombinant omega conotoxin MVIIA described strong analgesic activity for the recombinant peptide in animal models of pain, supporting the pharmacological rationale for the peptide class (PMID 17025374). Animal findings of that type sit behind the clinical program rather than within the indication itself.

Regulatory history of the indication

1. Venom peptide origin. A review of toxins in drug discovery traced the path from cone snail venom peptides to approved therapeutics and identified ziconotide as a worked example of that route (PMID 25448391).
2. Investigational period. The 2000 evaluation of intrathecal ziconotide discussed the agent as an investigational intrathecal analgesic under study for chronic pain (PMID 11060815).
3. United States approval in 2004. Approval established the single severe chronic pain indication quoted above, restricted to intrathecal use in adults.
4. Post approval reviews. A 2006 review characterised the approved product as a nonopioid intrathecal analgesic for chronic pain and described its clinical profile after launch (PMID 17078783).
5. Continuing literature. A 2023 bibliometric review of cone snail peptide toxin publications from 2000 to 2022 reported sustained research output on this peptide family and identified ziconotide as the approved member of the class (PMID 36976203).

The indication wording has remained a single severe chronic pain indication rather than expanding into disease specific claims. Labeling is revised periodically, and the current prescribing information for the product is the authoritative source for the exact present wording.

Adverse Events: What Studies Report

Published reviews of ziconotide emphasise that the safety profile shapes how the approved indication is applied. A 2006 review of ziconotide as an intrathecal analgesic reported central nervous system and psychiatric adverse effects among the principal tolerability concerns and described a narrow margin between analgesic effect and adverse effect that required careful clinical supervision during intrathecal therapy (PMID 17078783). The 2005 palliative care review reported that neuropsychiatric adverse effects and the need for close monitoring were central considerations when researchers and clinicians assessed the agent for patients with advanced illness (PMID 16225359). The earlier 2000 evaluation of intrathecal ziconotide also reported adverse effects associated with intrathecal infusion in chronic pain populations during the investigational period (PMID 11060815). Full warnings, contraindications and monitoring requirements appear in the prescribing information and are matters for the treating clinician.

One note on uses outside the label

Several published items describe ziconotide in settings that are not approved uses. A 2022 case report in Cureus described intrathecal ziconotide examined as a potential treatment for chronic migraine, which the authors presented as an exploratory observation rather than an established indication (PMID 35505713). A 2023 pharmaceutical study examined the physicochemical stability of a morphine, ropivacaine and ziconotide admixture in implantable pumps for intrathecal administration, and reported laboratory stability data rather than clinical outcomes for a combination product (PMID 35088750). Separately, research on other cone snail peptides continues, including a 2015 report on alphaO conotoxin GeXIVA as a potent alpha9alpha10 nicotinic acetylcholine receptor antagonist, which is a distinct investigational peptide and not ziconotide (PMID 26170295). None of these represent approved indications.

Questions a prescribing clinician can answer

Decisions about intrathecal therapy sit entirely with the specialist team managing the infusion system. Topics patients and caregivers commonly raise with that team include:

• Whether a given pain presentation matches the labeled indication wording for severe chronic pain in adults.
• How the agent compares with intrathecal morphine or other intrathecal options in a specific case.
• What monitoring the prescribing information specifies and who performs it.
• What the contraindications, warnings and psychiatric history screening requirements are for this product.
• How the infusion device is managed and who is responsible for it.

Background on the peptide itself is collected on the ziconotide overview page. This page summarises published literature and labeling for educational purposes only and is not medical advice; a licensed physician should answer every question about personal use.

References

• An evaluation of intrathecal ziconotide for the treatment of chronic pain (Expert Opinion on Investigational Drugs, 2000)
• Ziconotide: can we use it in palliative care? (American Journal of Hospice and Palliative Care, 2005)
• Recombinant omega-conotoxin MVIIA possesses strong analgesic activity (BioDrugs, 2006)
• Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain (Expert Review of Neurotherapeutics, 2006)
• Drug development from marine natural products (Nature Reviews Drug Discovery, 2009)
• Conotoxins that confer therapeutic possibilities (Marine Drugs, 2012)
• Toxins and drug discovery (Toxicon, 2014)
• Cloning, synthesis, and characterization of alphaO-conotoxin GeXIVA, a potent alpha9alpha10 nicotinic acetylcholine receptor antagonist (PNAS, 2015)
• TAT-Modified omega-Conotoxin MVIIA for Crossing the Blood-Brain Barrier (Marine Drugs, 2019)
• Intrathecal Administration of Ziconotide as a Potential Treatment for Chronic Migraines (Cureus, 2022)
• Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration (Neuromodulation, 2023)
• Bibliometric Review of the Literature on Cone Snail Peptide Toxins from 2000 to 2022 (Marine Drugs, 2023)